Simultaneous detection of sibutramine and phenolphthalein in a diet jelly health food product that caused health problems.
Tomohide FukiwakeSachiyo OosawaHiroki YoshinoTatsuya ShinozukaMaki NishimuraRie ItoHiroshi AkimaPublished in: Analytical sciences : the international journal of the Japan Society for Analytical Chemistry (2022)
The Public Health Center in Chiba Prefecture, Japan, received a consultation from a resident of Chiba Prefecture who consumed a diet jelly health food product and experienced health problems. To investigate the cause of the health problems, we examined the two food products for the presence of pharmaceutical ingredients. A screening analysis using ultra-high-performance liquid chromatography with a photodiode array detector (UPLC-PDA) indicated the presence of sibutramine and phenolphthalein in the food product. Analysis using an ultra-high-performance liquid chromatography-quadrupole-Kingdon trap mass spectrometer (UHPLC-Q-Kingdon trap MS) confirmed the presence of sibutramine and phenolphthalein. Quantitative analysis using UPLC-PDA showed that sibutramine and phenolphthalein were present at 15 and 16 mg/bag and 2.4 and 2.6 mg/bag, respectively. According to the drug insert for sibutramine capsules in the United States, the recommended medicinal dose of sibutramine should not exceed 15 mg/day, and the amount ingested in the present case exceeded that value. The present study results indicated that ingestion of the jelly health food product may cause health problems.
Keyphrases
- public health
- mental health
- healthcare
- tandem mass spectrometry
- human health
- health information
- ultra high performance liquid chromatography
- simultaneous determination
- palliative care
- multiple sclerosis
- risk assessment
- emergency department
- magnetic resonance
- weight loss
- computed tomography
- bone marrow
- high performance liquid chromatography
- gas chromatography